FDA 483 - Allergan Sales, LLC - July 09, 2010

An FDA inspection of Allergan Inc. in Irvine, CA, from July 6-9, 2010, identified three observations. The firm failed to timely report serious and unexpected adverse drug experiences and did not submit annual periodic adverse drug experience reports or other annual reports within the required timeframes.